Global
About
Development milestones Mission&Vision Founder Research Achievement
Technology Platforms
Single domain antibody Five core technology platforms
PIPELINE
BUSINESS PARTNERSHIPS
Product Out-Licensing Co-Development
investor
Career development
Our Story Social Recruitment
News
Company News Media
Contact Us
Company Address Online Message
×
Our Story

Share the latest information

Our Story
News
Company News
Media
2025-04-28
Novamab will present the oral TL1A nanobody and long-acting TL1A bispecific antibody at the DDW 2025 conference
More
2023-01-06
The clinical trial of Novamab's inhaled TSLP nanoantibody drug LQ043H was approved by CDE
More
2022-11-30
LQ036, the world's first inhaled sdAb drug for the treatment of moderate and severe asthma, has completed the administration of the first patient in China's clinical phase I!
More
2022-11-29
The research results of Novamab long-acting IL-5 nanoantibody were published in Research Research!
More
2022-10-17
Novamab | Five years of joint efforts to start a new journey
More
2022-09-27
Novamab won the support of Shanghai's 2022 annual innovation fund plan
More
2022-09-16
Novamab was listed in "Top 100 Chinese pharmaceutical innovative seed enterprises in 2022"
More
2022-09-13
Novamab Biological announced the appointment of Ms. Huang Jing as the company's chief business officer
More
2022-09-08
Novamab won the nomination award of "Star of the Future" in biomedicine
More
2022-08-22
Celebrate the official commencement of GMP production!
More
2022-07-15
Novamab participated in the development of COVID-19 neutralizing antibody molecular imaging technology, and the research results were published in Research!
More
总计 49 12345